A research team led by Dr. SHENG Nengyin of the Kunming Institute of Zoology (KIZ) of the Chinese Academy of Sciences has reframed ZC4H2-associated rare disorder (ZARD)—a disorder marked by intellectual disability, developmental delays, muscle weakness, and other neurological or physical abnormalities—as a "disease spectrum" rather than a condition driven by a single mechanism.
Previously, the team demonstrated that ZC4H2 acts as a postsynaptic regulator of excitatory synaptic activity and brain cognition by modulating the protein stability of AMPA receptor subunits GluA1 and GluA2 (PMID: 40632560). However, it was unclear whether the same pathological mechanisms were at work in patients carrying different ZC4H2 variants, despite their clinical similarities.
Now, in more recent research, the team has shown that different pathogenic mutations in the same gene can produce nearly identical cognitive deficits through diametrically opposite synaptic mechanisms. The findings suggest that intervention should be guided by the specific mutation, rather than the diagnosis alone.
The findings were published in Neuron on November 5.
In this new study, the team first expressed wild-type ZC4H2 and 23 pathogenic mutants in N2A cells. They identified two distinct classes: one that lost the ability to regulate excitatory AMPA receptor subunits GluA1/GluA2 (loss-of-function) and another that retained AMPA regulation but abnormally suppressed inhibitory GABAA receptor subunits α1/β1 (gain-of-function).
Electrophysiological recordings on hippocampal slices confirmed that the two classes specifically disrupted inhibitory and excitatory transmission, respectively.
To link mechanism to behavior, the researchers generated two knock-in mouse models carrying representative patient mutations: ZC4H2L66H/y and ZC4H2R213W/y. Both showed comparable cognitive deficits, including impaired novel-object recognition, social-memory loss, and defective spatial learning, without obvious motor or anxiety abnormalities.
However, their synaptic readouts pointed in opposite directions. ZC4H2L66H/y mice showed weakened GABAergic inhibitory transmission and impaired inhibitory long-term potentiation (LTP), while ZC4H2R213W/y mice showed heightened AMPAR-mediated excitatory transmission and impaired excitatory LTP.
Using TurboID proximity labeling, the team traced the divergence to two different E3 ubiquitin ligase pathways.
The L66H mutant developed a new interaction with makorin ring finger protein 2 (MKRN2), which promotes polyubiquitination and destabilization of GABAA receptor subunits. The R213W mutant, by contrast, disrupted ZC4H2's interaction with ring finger protein 220 (RNF220), reducing RNF220 stability and lowering ubiquitination of AMPA receptor subunits, leaving excitatory synapses overactive.
Genetic rescue experiments confirmed this specificity: forebrain excitatory-neuron knockout of MKRN2 rescued only the L66H model, while expression of a degradation-resistant RNF220 variant rescued only the R213W model.
The researchers also explored the therapeutic potential of two clinically used drugs. The GABAA agonist muscimol restored inhibitory transmission and cognition in ZC4H2L66H/y mice but had no effect in ZC4H2R213W/y mice, whereas the AMPAR antagonist perampanel produced the opposite result.
This contrasting response supports a mutation-stratified intervention strategy rather than a one-size-fits-all approach.
According to the researchers, the study's significance extends beyond ZARD. By demonstrating that phenotypic similarity can mask mechanistic opposition, it argues for incorporating molecular pathology—not just gene identity or clinical symptoms—into disease stratification for neurodevelopmental disorders.
In a field where more than 2,500 intellectual-disability genes are known, the work offers a generalizable principle: precision intervention requires matching the drug to the synaptic mechanism of the mutation.
